---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060049"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-02T00:03:19.384320+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aspira Q1 revenue $2.2M; OvaWatch volume up 114% YoY

## Summary
- Product revenue $2.2M, down 4% YoY; OvaSuite volume 5,829 units (-7%).
- Gross profit margin improved to 56% from 51% in Q1 2023.
- Cash used in operating activities $4.4M, down 22% YoY; 2024 target stays $15-18M.
- OvaWatch volume grew 114% YoY; longitudinal monitoring feature launched.
- New Anthem Blue Cross CA coverage agreement for OvaSuite effective June 1, 2024.

## SEC filing metadata
- accession: 0000950170-24-060049
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000095017024060049/0000950170-24-060049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000095017024060049/awh-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060049
- JSON: https://secwatch.observer/filing/0000950170-24-060049.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060049.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. reported first quarter ended March 31, 2024 results: revenue $2.2 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $2.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: by reference language in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Aspira Women’s Health Reports First Quarter 2024 Financial Results Q1 2024 OvaSuite SM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN,
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000095017024060049/0000950170-24-060049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.